EP Patent

EP3045466A1 — (2s,3r,4s,5s,6r)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol propylene glycol solvate as sgt2 inhibitor for the treatment of diabetes

Assigned to AstraZeneca AB · Expires 2016-07-20 · 10y expired

What this patent protects

The present invention relates to the propylene glycol solvate of (2S,3R,4S,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl] -6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol (formula I): as SGT2 inhibitor for the treatment of diabetes.

USPTO Abstract

The present invention relates to the propylene glycol solvate of (2S,3R,4S,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl] -6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol (formula I): as SGT2 inhibitor for the treatment of diabetes.

Drugs covered by this patent

Patent Metadata

Patent number
EP3045466A1
Jurisdiction
EP
Classification
—
Expires
2016-07-20
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.